AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Jul 05, 2022

PeerView Live: Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

Saturday, July 23


Aadia22 Ind High Graphic

Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease.

Join us for this PeerView MasterClass and Practicum in which a panel of PN experts will offer evidence-based, practical guidance on current diagnostic and treatment strategies, and the latest clinical data regarding novel therapies. Their discussion will be enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment.

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

When: Saturday, July 23 | 7 a.m. Registration and Breakfast | 7:30 a.m. Program

Where: MacKenzie Ballroom | Fairmont Waterfront 

Interesting Stories
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
More in 2022 AAD Innovation Academy
Keira L. Barr, MD, FAAD
2022 AAD Innovation Academy
Unlocking the secrets of mind-body therapy
Jul 29, 2022
Robert T. Brodell, MD, FAAD
2022 AAD Innovation Academy
Fox Lecture: Access belongs to everyone
Jul 29, 2022
Img 9508
2022 AAD Innovation Academy
AAD debuts Innovation Academy in Vancouver
Jul 29, 2022
Edit Olasz Harken, MD, PhD, FAAD
2022 AAD Innovation Academy
Your name can be your skin care brand
Jul 29, 2022
Pearl E. Grimes, MD, FAAD
2022 AAD Innovation Academy
Kelly Lectureship traces advances in pigmentary diseases
Jul 29, 2022
Pearl Grimes, MD, FAAD, and Robert T. Brodell, MD, FAAD, FRCP
2022 AAD Innovation Academy
Saturday’s named lectureships take the stage
Jul 23, 2022
Jason B. Lee, MD, FAAD
2022 AAD Innovation Academy
How are your diagnostic skills?
Jul 23, 2022
Lindsay Strowd, MD, FAAD
2022 AAD Innovation Academy
Consultive dermatology plugs in post pandemic
Jul 23, 2022
Mehdi Rashighi, MD, FAAD
2022 AAD Innovation Academy
Game-changing new treatments evolve for dermatologic conditions
Jul 23, 2022
Carolyn Goh, MD, FAAD
2022 AAD Innovation Academy
New approaches to managing hair disorders
Jul 23, 2022
So Yeon Paek, MD, FAAD
2022 AAD Innovation Academy
Laser focused
Jul 22, 2022
Brett A. King, MD, PhD, FAAD
2022 AAD Innovation Academy
JAK inhibitors revolutionize dermatology
Jul 22, 2022
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.